Last reviewed · How we verify
B013
At a glance
| Generic name | B013 |
|---|---|
| Sponsor | Shanghai Jiaolian Drug Research and Development Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of B013 and Nab-Paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer (PHASE2, PHASE3)
- A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- B013 CI brief — competitive landscape report
- B013 updates RSS · CI watch RSS
- Shanghai Jiaolian Drug Research and Development Co., Ltd portfolio CI